News
After nearly 27 years as a division of Swiss giant Novartis, generics and biosimilars specialist Sandoz (SWX: SDZ) went its ...
The US Food and Drug Administration (FDA) approved San Diego, USA-based LENZ Therapeutics’ VIZZ (aceclidine ophthalmic ...
England has agreed to commission the use of Hemlibra (emicizumab) as a prophylactic treatment for patients of all ages with ...
Among last week’s news, US biotech Celcuity leapt 180% on new Phase III data for its cancer drug candidate gedatolisib. US drugmaker Madrigal Pharmaceuticals entered into a licensing deal with China’s ...
Swiss pharma giant Roche announced positive five-year efficacy, safety and durability data from the Phase III Portal study, a ...
German healthcare and crop sciences giant Bayer (BAYN DE) saw its share close up 2.8% at 28.12 euros, after it provided an ...
Frazier Life Sciences (FLS), a US investment firm focused on innovative therapeutics, has announced the closing of its ...
The US Food and Drug Administration (FDA) is requiring safety labeling changes to all opioid pain medications to better ...
For the first time in decades, the pharmaceutical industry has been directly affected by a geopolitical trade negotiation ...
US RNA interference (RNAi)specialist Arrowhead Pharmaceuticals (Nasdaq: ARWR) today announced that its majority-owned subsidiary Visirna Therapeutics has signed an asset purchase agreement with France ...
US mRNA specialist Moderna has today reported financial results and provided business updates for the second quarter of 2025, ...
US mRNA specialist Moderna has announced that the UK Court of Appeal has upheld the validity of its EP'949 patent.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results